

## Enhanced Cell-potent Peptidomimetic Inhibitors for NTMT1/2

**Highly selective and cell-permeable inhibitors of N-terminal methylation provide a potential therapeutic approach for treating glioblastoma and cervical cancers while advancing stem cell research.**

NCS: Researchers at Purdue University have designed a series of new peptidomimetic inhibitors for protein alpha-N-terminal methyltransferases (NTMTs). NTMTs recognize a unique N-terminal of a protein and catalyze the addition of 1-3 methyl group(s) to it. The exact role and function of NTMTs is unknown, but NTMT1 plays an important role in mitosis, DNA damage repair, stem cell maintenance, glioblastoma, and cervical cell proliferation and migration. NTMT1 is a potential anti-cancer target as it is overexpressed in several cancers such as gastrointestinal, colorectal and melanoma. To improve the cellular inhibition activity of previously invented peptidomimetic inhibitors, the Purdue researchers designed several cell-potent peptidomimetic inhibitors of N-terminal methylation. These inhibitors displayed not only increased cellular inhibition, but they were also optimized for increased hydrophobicity which co-relates with increased cell permeability. The most potent inhibitor (IC<sub>50</sub> = 0.9  $\mu$ M) exhibited over 2-fold increased inhibition on cellular N-terminal methylation levels with a cellular IC<sub>50</sub> value of  $\sim$ 50  $\text{\AA}$  $\mu$ M compared to previously reported peptidomimetic inhibitors of NTMT1. It also exhibited over 300-fold selectivity to several other methyltransferases. These cell-potent inhibitors serve as valuable tools to study the function and role of NTMTs and the alpha-N-terminal methylation pathway in cancer and stem cell maintenance.

**Technology Validation:** In vitro cytotoxicity studies were conducted in normal and NTMT1 knock-out HCT116 cells.

Related Publications:

G Dong, ID Iyamu, JZ Vilseck, D Chen, R Huang. (2022) Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal

**Technology ID**

2022-HUAN-69636

**Category**

Pharmaceuticals/Other

Pharmaceuticals/Research Tools  
& Assays

**Authors**

Dongxing Chen

Guangping Dong

Rong Huang

**Further information**

Joe Kasper

[JKasper@prf.org](mailto:JKasper@prf.org)

Nathan Smith

[nesmith@prf.org](mailto:nesmith@prf.org)

**View online**



Methyltransferase 1. *Molecules*, 27, 1381. <https://www.mdpi.com/1420-3049/27/4/1381>

Chen D, Dong G, Deng Y, Noinaj N, Huang R. (2021) Structure-based Discovery of Cell-potent Peptidomimetic Inhibitors for Protein N-terminal Methyltransferase 1. *ACS Medicinal Chemistry Letters*. 12, 485-493. <https://pubs.acs.org/doi/full/10.1021/acsmchemlett.1c00012>

Mackie BD, Chen D, Dong G, Dong C, Parker H, Schaner Tooley C, Noinaj N, Min J, Huang R. (2020) Selective Peptidomimetic Inhibitors of NTMT1/2: Rational design, synthesis, characterization, and crystallographic studies. *Journal of Medicinal Chemistry*. 63, 9512-9522. PMID: 32689795. PMCID: PMC74286280. <https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00689>

### **Advantages**

- Fully characterized in biochemical and biophysical methods
- highly effective inhibition of N-terminal methylation
- high selectivity to a panel of methyltransferases

### **Applications**

- novel cancer treatment for cervical cancer and glioblastoma
- stem cell therapy
- studying NTMTs and the alpha-N-terminal methylation pathway

**TRL:** 2

### **Intellectual Property:**

Provisional-Gov. Funding, 2022-02-03, United States | PCT-Gov. Funding, 2022-12-02, WO | NATL-Patent, 2024-07-16, United States

**Keywords:** peptidomimetic inhibitors, protein N-terminal methyltransferases, NTMTs, NTMT1 inhibitor, anti-cancer target, N-terminal methylation, cellular inhibition, glioblastoma treatment, cervical cancer treatment, stem cell therapy

Explore other available products test at [The Office of Technology Commercialization Online Licensing Store](#)